Search Results - "FERRERO, J. M"

Pertuzumab, trastuzumab, and standard anthracycline- and taxane-based chemotherapy for the neoadjuvant treatment of patients with HER2-positive localized breast cancer (BERENICE): a phase II, open-label, multicenter, multinational cardiac safety study by Swain, S.M., Ewer, M.S., Viale, G., Delaloge, S., Ferrero, J.-M., Verrill, M., Colomer, R., Vieira, C., Werner, T.L., Douthwaite, H., Bradley, D., Waldron-Lynch, M., Kiermaier, A., Eng-Wong, J., Dang, C.

“…Anti-HER2 therapies are associated with a risk of increased cardiac toxicity, particularly when part of anthracycline-containing regimens. We report cardiac…”
Get full text

Letrozole and palbociclib versus chemotherapy as neoadjuvant therapy of high-risk luminal breast cancer by Cottu, P., D'Hondt, V., Dureau, S., Lerebours, F., Desmoulins, I., Heudel, P.-E., Duhoux, F.P., Levy, C., Mouret-Reynier, M.-A., Dalenc, F., Frenel, J.-S., Jouannaud, C., Venat-Bouvet, L., Nguyen, S., Ferrero, J.-M., Canon, J.-L., Grenier, J., Callens, C., Gentien, D., Lemonnier, J., Vincent-Salomon, A., Delaloge, S.

“…Palbociclib is a CDK4/6 inhibitor with demonstrated efficacy and safety in combination with endocrine therapy in advanced luminal breast cancer (LBC). We…”
Get full text

Prognostic factors in 1038 women with metastatic breast cancer by Largillier, R., Ferrero, J.-M., Doyen, J., Barriere, J., Namer, M., Mari, V., Courdi, A., Hannoun-Levi, J. M., Ettore, F., Birtwisle-Peyrottes, I., Balu-Maestro, C., Marcy, P. Y., Raoust, I., Lallement, M., Chamorey, E.

“…Background: Treatment of metastatic breast cancer (MBC) remains palliative. Patients with MBC represent a heterogeneous group whose prognosis and outcome may…”
Get full text

Translational studies within the TAMRAD randomized GINECO trial: evidence for mTORC1 activation marker as a predictive factor for everolimus efficacy in advanced breast cancer by Treilleux, I., Arnedos, M., Cropet, C., Wang, Q., Ferrero, J.-M., Abadie-Lacourtoisie, S., Levy, C., Legouffe, E., Lortholary, A., Pujade-Lauraine, E., Bourcier, A.-V., Eymard, J.-C., Spaeth, D., Bachelot, T.

“…Everolimus is an agent frequently associated with specific toxicities. Predictive markers of efficacy are needed to help define which patients could benefit…”
Get full text

Efficacy of front-line treatment for hormone receptor-positive HER2-negative metastatic breast cancer with germline BRCA1/2 mutation by Frenel, J.-S., Lusque, A., Delaloge, S., Ferrero, J.-M., Bachelot, T., Desmoulins, I., Levy, C., Eymard, J.-C., Gonçalves, A., Patsouris, A., Reynier, M. A. Mouret, Thery, M. J.-C., Petit, T., Cabel, L., Uwer, L., Debled, M., Chevrot, M., Mailliez, A., Jacot, W., de La Motte Rouge, T.

“…Background Efficacy of endocrine therapy in HR+/HER2− metastatic breast cancer could differ depending on the presence of BRCA1/2 germline mutation. Methods The…”
Get full text

A randomized controlled phase II trial of a novel composition of paclitaxel embedded into neutral and cationic lipids targeting tumor endothelial cells in advanced triple-negative breast cancer (TNBC) by Awada, A., Bondarenko, I.N., Bonneterre, J., Nowara, E., Ferrero, J.M., Bakshi, A.V., Wilke, C., Piccart, M.

“…EndoTAG-1, composed of paclitaxel embedded in liposomal membranes targeting tumor endothelial cells, was evaluated for safety and efficacy in advanced…”
Get full text

Evolution of overall survival and receipt of new therapies by subtype among 20 446 metastatic breast cancer patients in the 2008-2017 ESME cohort by Grinda, T., Antoine, A., Jacot, W., Blaye, C., Cottu, P.-H., Diéras, V., Dalenc, F., Gonçalves, A., Debled, M., Patsouris, A., Mouret-Reynier, M.-A., Mailliez, A., Clatot, F., Levy, C., Ferrero, J.-M., Desmoulins, I., Uwer, L., Petit, T., Jouannaud, C., Lacroix-Triki, M., Deluche, E., Robain, M., Courtinard, C., Bachelot, T., Brain, E., Pérol, D., Delaloge, S.

“…Treatment strategies for metastatic breast cancer (MBC) have made great strides over the past 10 years. Real-world data allow us to evaluate the actual benefit…”
Get full text

Enrollment of older metastatic breast cancer patients in first-line clinical trials: 9-year experience of the large-scale real-life multicenter French ESME cohort by Bringuier, M., Carton, M., Levy, C., Patsouris, A., Pasquier, D., Debled, M., Rigal, O., Jacot, W., Gonçalves, A., Desmoulins, I., De La Motte Rouge, T., Bachelot, T., Ferrero, J.-M., Eymard, J.-C., Ung, M., Mouret-Reynier, M.-A., Petit, T., Chevrot, M., Uwer, L., Courtinard, C., Frenel, J.-S., Vianzone, A., Baldini, C.

“…Purpose Older cancer patients are underrepresented in clinical trials. We aimed to evaluate the enrollment of older women aged 70 years old (yo) or over with…”
Get full text

Circulating tumor cells and brain metastasis outcome in patients with HER2-positive breast cancer: the LANDSCAPE trial by Pierga, J.-Y., Bidard, F.-C., Cropet, C., Tresca, P., Dalenc, F., Romieu, G., Campone, M., Mahier Aït-Oukhatar, C., Le Rhun, E., Gonçalves, A., Leheurteur, M., Dômont, J., Gutierrez, M., Curé, H., Ferrero, J.-M., Labbe-Devilliers, C., Bachelot, T.

“…Decrease of circulating tumor cells (CTC) during treatment is an independent prognostic factor in metastatic breast cancer (MBC). We specifically evaluated the…”
Get full text

Second-line chemotherapy with pegylated liposomal doxorubicin and carboplatin is highly effective in patients with advanced ovarian cancer in late relapse: a GINECO phase II trial by Ferrero, J.-M., Weber, B., Geay, J.-F., Lepille, D., Orfeuvre, H., Combe, M., Mayer, F., Leduc, B., Bourgeois, H., Paraiso, D., Pujade-Lauraine, E.

“…Background: Platinum-based chemotherapy is standard second-line treatment of patients with advanced ovarian cancer (AOC) in late relapse. Pegylated liposomal…”
Get full text

Aromatase inhibition in male breast cancer patients: biological and clinical implications by Doyen, J., Italiano, A., Largillier, R., Ferrero, J.-M., Fontana, X., Thyss, A.

“…The role of aromatase inhibitors (AIs) and their impact on estradiol (E2) levels remain unknown in male breast cancer (MBC) patients. MBC patients with…”
Get full text

Circulating tumour cells and pathological complete response: independent prognostic factors in inflammatory breast cancer in a pooled analysis of two multicentre phase II trials (BEVERLY-1 and -2) of neoadjuvant chemotherapy combined with bevacizumab by Pierga, J.-Y., Bidard, F.-C., Autret, A., Petit, T., Andre, F., Dalenc, F., Levy, C., Ferrero, J.-M., Romieu, G., Bonneterre, J., Lerebours, F., Bachelot, T., Kerbrat, P., Campone, M., Eymard, J.-C., Mouret-Reynier, M.-A., Gligorov, J., Hardy-Bessard, A.-C., Lortholary, A., Soulie, P., Boher, J.-M., Proudhon, C., Charafe-Jaufret, E., Lemonnier, J., Bertucci, F., Viens, P.

“…We present a pooled analysis of predictive and prognostic values of circulating tumour cells (CTC) and circulating endothelial cells (CEC) in two prospective…”
Get full text

Intraoperative radiological margin assessment in breast-conserving surgery by Ihrai, T, Quaranta, D, Fouche, Y, Machiavello, J.-C, Raoust, I, Chapellier, C, Maestro, C, Marcy, M, Ferrero, J.-M, Flipo, B

“…Abstract A prospective study was lead in order to analyze the accuracy of an X-ray device settled in the operating room for margin assessment, when performing…”
Get full text

Endocrine therapy or chemotherapy as first-line therapy in hormone receptor–positive HER2-negative metastatic breast cancer patients by Jacquet, E., Lardy-Cléaud, A., Pistilli, B., Franck, S., Cottu, P., Delaloge, S., Debled, M., Vanlemmens, L., Leheurteur, M., Guizard, A.V., Laborde, L., Uwer, L., Jacot, W., Berchery, D., Desmoulins, I., Ferrero, J.M., Perrocheau, G., Courtinard, C., Brain, E., Chabaud, S., Robain, M., Bachelot, T.

“…For hormone receptor–positive (HR+) human epidermal growth factor receptor 2 (HER2-) negative metastatic breast cancer (MBC), international guidelines…”
Get full text

Prognostic factors in 401 elderly women with metastatic breast cancer by Follana, P, Barrière, J, Chamorey, E, Largillier, R, Dadone, B, Mari, V, Hannoun-Levi, J M, Marcy, M, Flipo, B, Ferrero, J-M

“…Elderly patients with metastatic breast cancer have a prognosis and outcome that may be dependent on a host of factors. We retrospectively analyzed 401 female…”
Get more information

Prostate-specific antigen doubling time before onset of chemotherapy as a predictor of survival for hormone-refractory prostate cancer patients by Oudard, S., Banu, E., Scotte, F., Banu, A., Medioni, J., Beuzeboc, P., Joly, F., Ferrero, J.-M., Goldwasser, F., Andrieu, J.-M.

“…Background: We evaluated the possible use of prostate-specific antigen doubling time (PSA-DT) before chemotherapy initiation as a surrogate marker of survival…”
Get full text

Sefety profile of subcutaneous trastuzumab in patients with HER2-positive early breast cancer: The French HERMIONE non-interventional prospective study by Jacquin, J.-P.P., Uwer, L., Savignoni, A., Ferrero, J.-M., Lortholary, A., Solub, D., Attar-Rabia, H., Deblay, S., Pibre, S., Belkacemi, Y.

Get full text

UNICANCER-PEGASE 07 study: a randomized phase III trial evaluating postoperative docetaxel–5FU regimen after neoadjuvant dose-intense chemotherapy for treatment of inflammatory breast cancer by Gonçalves, A., Pierga, J.-Y., Ferrero, J.-M., Mouret-Reynier, M.-A., Bachelot, T., Delva, R., Fabbro, M., Lerebours, F., Lotz, J.-P., Linassier, C., Dohollou, N., Eymard, J.-C., Leduc, B., Lemonnier, J., Martin, A.-L., Boher, J.-M., Viens, P., Roché, H.

“…Inflammatory breast cancer (IBC) is a rare and aggressive disease requiring a multimodal treatment. We evaluated the benefit of adding docetaxel–5-fluorouracil…”
Get full text

Metastatic inflammatory breast cancer: survival outcomes and prognostic factors in the national, multicentric, and real-life French cohort (ESME) by Dano, D., Lardy-Cleaud, A., Monneur, A., Quenel-Tueux, N., Levy, C., Mouret-Reynier, M.-A., Coudert, B., Mailliez, A., Ferrero, J.-M., Guiu, S., Campone, M., de La Motte Rouge, T., Petit, T., Pistilli, B., Dalenc, F., Simon, G., Lerebours, F., Chabaud, S., Bertucci, F., Gonçalves, A.

“…Primary inflammatory breast cancer (IBC) is a rare and aggressive entity whose prognosis has been improved by multimodal therapy. However, 5-year overall…”
Get full text

Updated results of GETUG-12, a phase III trial of docetaxel-based chemotherapy in high-risk localized prostate cancer, with a 12-year follow-up by Fizazi, K., Carmel, A., Joly, F., Delva, R., Gravis, G., Rolland, F., Priou, F., Ferrero, J.-M., Houede, N., Mourey, L., Theodore, C., Krakowski, I., Berdah, J.-F., Baciuchka Palmaro, M., Laguerre, B., Flechon, A., Ravaud, A., Brihoum, M., Culine, S., Le Teuff, G.

Get full text